New drug duo targets hard-to-treat thyroid cancers

NCT ID NCT06007924

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, avutometinib and defactinib, can shrink or control certain types of advanced thyroid cancer that no longer respond to standard radioactive iodine treatment. The trial enrolls 30 adults with RAF dimer-driven differentiated or anaplastic thyroid cancer. Researchers will measure how many patients respond and track side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RAF DIMER-DRIVEN ANAPLASTIC THYROID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)

    RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    RECRUITING

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    RECRUITING

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.